31 March 2023
Comirnaty COVID-10 vaccines from Pfizer AG: authorisation without special conditions approved
Swissmedic has approved Pfizer AG's applications to have the company’s COVID-19 vaccines – until now authorised temporarily subject to special conditions – authorised for five years. This decision was based on a large amount of data on the safety, efficacy, and quality of the vaccines which the company has now submitted in compliance with the conditions set.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar